Journal of Neurology

, Volume 252, Supplement 4, pp iv32–iv36 | Cite as

Levodopa therapy from the neuroprotection viewpoint

From a clinical outlook
  • Tomoyoshi KondoEmail author


There are many reports indicating the existence of free radical adducts in the Parkinson’s disease (PD) brain. However, levodopa may have two aspects in its characteristics, one is that levodopa is a source of free radicals in the pathogenesis of PD, and the other is that it is the precursor of the most efficient transmitter in dopaminergic neurons from the viewpoint of therapy. Dopamine (DA) supplemented by levodopa acts as a neural transmitter and as a dopaminergic receptor-mediated trophic agent. From studies using rodent models of parkinsonism, physical exercise potentially induces neurotrophins in the brain and protects or enhances the regeneration of nigrostriatal neurons. In our preliminary experiment, the potential effects of physical exercise on motor and psychological symptoms were observed, suggesting that physical exercise may, to a certain extent, modulate pathological conditions in the brain. On the basis of the above we conclude that DA supplementation in PD potentially increases the levels of neurotrophins in a dopaminergic receptor-mediated manner, and secondarily enhances mobility (physical exercise). In general, levodopa demand increases with disease progression, and physical therapy is more important in advanced stages. To obtain good outcomes of physical exercise, it is essential to maintain a good medical control, particularly at the advanced stages of PD. From these results, it can be speculated that levodopa exerts some neuroprotective effects as long as the dose is not excessively high.

Key words

Parkinson’s disease levodopa dopamine free radicals neuroprotection 


  1. 1.
    Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5(1):77–82PubMedGoogle Scholar
  2. 2.
    Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3.4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res 989(2):205–213CrossRefPubMedGoogle Scholar
  3. 3.
    Machida Y, Chiba T, Takayanagi A, Tanaka Y, Asanuma M, Ogawa N, Koyama A, Iwatsubo T, Ito S, Jansen PH, Shimizu N, Tanaka K, Mizuno Y, Hattori N (2005) Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun 332(1):233–240CrossRefPubMedGoogle Scholar
  4. 4.
    Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8(2):95–100CrossRefPubMedGoogle Scholar
  5. 5.
    Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653–1661CrossRefPubMedGoogle Scholar
  6. 6.
    Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54(1):93–101CrossRefPubMedGoogle Scholar
  7. 7.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508CrossRefPubMedGoogle Scholar
  8. 8.
    Haavik J, Almas B, Flatmark T (1997) Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons? J Neurochem 68(1):328–332PubMedGoogle Scholar
  9. 9.
    Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53 (Suppl 3):S26–S36CrossRefPubMedGoogle Scholar
  10. 10.
    Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 32(6):804–812CrossRefPubMedGoogle Scholar
  11. 11.
    McLaughlin BA, Nelson D, Erecinska M, Chesselet MF (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J Neurochem70(6):2406–2415PubMedGoogle Scholar
  12. 12.
    Han SK, Mytilineou C, Cohen G (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66(2):501–510PubMedGoogle Scholar
  13. 13.
    Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304(2):792–800CrossRefPubMedGoogle Scholar
  14. 14.
    Quinn N, Parkes D, Janota I, Marsden CD (1986) Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1(1):65–68CrossRefPubMedGoogle Scholar
  15. 15.
    Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8(2):95–100CrossRefPubMedGoogle Scholar
  16. 16.
    Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A (1994) Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 25; 171(1–2):55–58CrossRefGoogle Scholar
  17. 17.
    Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43(5):561–575CrossRefPubMedGoogle Scholar
  18. 18.
    Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 56(11 Suppl 5):S1–S88Google Scholar
  19. 19.
    Miziuno Y, Okuma Y, Kikuchi S, Kuno S, Hashimoto T, Hasegawa K, Mano Y, Miwa H, Murata M, Yamamoto M, Yokochi F, Okiyama R, Kanazawa A, Shinpo K, Chuma T, Higashi T, Maruyama T, Mizuta E, Yamazaki S; Ad Hoc Committee on the Guidelines for the Treatment of Parkinson’s Disease, Japanese Neurological Society (2002) A guideline for the treatment of Parkinson’s disease. Rinsho Shinkeigaku 42(5):421–494PubMedGoogle Scholar
  20. 20.
    Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127(7):1696–1702CrossRefPubMedGoogle Scholar
  21. 21.
    Jenner P (2003) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson’s disease. Curr Opin Neurol 16(Suppl 1):S3–S7Google Scholar
  22. 22.
    Hoehn MM (1992) The natural history of Parkinson’s disease in the prelevodopa and post-levodopa eras. Neurol Clin 10(2):331–339PubMedGoogle Scholar
  23. 23.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484–1491CrossRefPubMedGoogle Scholar
  24. 24.
    Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Kimura J, Shimohama S (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 44(1):110–119CrossRefPubMedGoogle Scholar
  25. 25.
    Kobayashi S, Ogren SO, Hoffer BJ, Olson L (1998) Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Exp Neurol 154(2):302–314CrossRefPubMedGoogle Scholar
  26. 26.
    Ohta K, Fujinami A, Kuno S, Sakakimoto A, Matsui H, Kawahara Y, Ohta M (2004) Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71(3):162–168CrossRefPubMedGoogle Scholar
  27. 27.
    Guo H, Tang Z,Yu Y, Xu L, Jin G, Zhou J (2002) Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci 16(10):1861–1870CrossRefPubMedGoogle Scholar
  28. 28.
    Bozzi Y, Vallone D, Borrelli E (2000) Neuroprotective role of dopamine against hippocampal cell death. J Neurosci 20(22):8643–8649Google Scholar
  29. 29.
    Tripanichkul W, Stanic D, Drago J, Finkelstein DI, Horne MK (2003) D2 Dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions. Eur J Neurosci 17(5):1033–1045CrossRefPubMedGoogle Scholar
  30. 30.
    Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I (1992) Dopaminergic stimulation up-regulates the in vivo expression of brainderived neurotrophic factor (BDNF) in the striatum. FEBS Lett 313(2):138–142CrossRefPubMedGoogle Scholar
  31. 31.
    Lytle ME, Vander Bilt J, Pandav RS, Dodge HH, Ganguli M (2004) Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord 18:57–64CrossRefPubMedGoogle Scholar
  32. 32.
    Hiwatani H, Miwa H, Kondo T, Kajimoto Y (2005) Effects of leg muscle on Parkinson’s disease patients. Parkinsonism Relat Disord 11(Suppl 2):248Google Scholar
  33. 33.
    Mabandla M, Kellaway L, St Clair Gibson A, Russell VA (2004) Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab Brain Dis 19:43–50CrossRefPubMedGoogle Scholar
  34. 34.
    Smith AD, Zigmond MJ (2003) Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol 184:31–39CrossRefPubMedGoogle Scholar
  35. 35.
    Tillerson JL, Caudle WM, Reveron ME, Miller GW (2003) Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson’s disease. Neuroscience 119:899–911CrossRefPubMedGoogle Scholar
  36. 36.
    Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ (2003) Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 85:299–305CrossRefPubMedGoogle Scholar
  37. 37.
    Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK, Jakowec MW (2005) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77:378–390CrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  1. 1.Dept. of NeurologyWakayama Medical UniversityWakayama 641-8510Japan

Personalised recommendations